TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31427326

Group type: EXPERIMENTAL
Intervention: Genie intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 28959492

Group type: EXPERIMENTAL
Intervention: Low-dose alteplase (0.6 mg/kg)
Number of subjects: 3310

Group type: COMPARATOR
Intervention: Standard-dose alteplase (0.9 mg/kg)
Number of subjects: 3310
Study: 27002298

Group type: EXPERIMENTAL
Intervention: Trabodenoson 500 mcg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24647384

Group type: EXPERIMENTAL
Intervention: Web-based intervention providing personalized CVD risk information and behavioral/lifestyle modules (3-month duration).
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 96
Study: 21799028

Group type: EXPERIMENTAL
Intervention: ICS + LABA + Tio
Number of subjects: 2853

Group type: COMPARATOR
Intervention: ICS + LABA
Number of subjects: 2853
Study: 19490181

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (DF), n=23
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Abacavir (ABC), n=24
Number of subjects: 47

Group type: COMPARATOR
Intervention: Thymidine NRTIs (zidovudine and stavudine), n=11 and n=36 respectively
Number of subjects: 47
Study: 17241298

Group type: EXPERIMENTAL
Intervention: PAC7 group (omeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg twice daily for 7 days)
Number of subjects: 598

Group type: COMPARATOR
Intervention: PAC14 group (same regimen for 14 days)
Number of subjects: 598
Study: 16079650

Group type: EXPERIMENTAL
Intervention: 6 months of aerobic training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (sedentary lifestyle)
Number of subjects: 18
Study: 11986086

Group type: EXPERIMENTAL
Intervention: Cidofovir 1% four times daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cidofovir 1% ten times daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cidofovir 1% four times daily and Cyclosporin A 1% four times daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sodium chloride four times daily
Number of subjects: 34
Study: 9704869

Group type: EXPERIMENTAL
Intervention: Lithium (1200 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7625773

Group type: EXPERIMENTAL
Intervention: Glycerol administration (20 g) alone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Glycerol administration (20 g) with a mixed meal
Number of subjects: 13

Group type: COMPARATOR
Intervention: Mixed meal alone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Glycerol administration (20 g)
Number of subjects: 13
Study: 30947531

Group type: EXPERIMENTAL
Intervention: sustained-release bupropion (switch)
Number of subjects: 1522

Group type: EXPERIMENTAL
Intervention: sustained-release bupropion (combination)
Number of subjects: 1522

Group type: EXPERIMENTAL
Intervention: aripiprazole (augmentation)
Number of subjects: 1522
Study: 28114909

Group type: EXPERIMENTAL
Intervention: High intensity treatment (HIT) composed of low glycemic index diet + exercise + vitamin D (60ng/mL serum concentration)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Lower intensity treatment (LITE) with general advice to follow a healthy diet and exercise pattern + vitamin D to avoid insufficiency
Number of subjects: 506
Study: 25451240

Group type: EXPERIMENTAL
Intervention: GABA-ergic neurotransmission via alprazolam (GABAA receptor agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23660044

Group type: EXPERIMENTAL
Intervention: Educational intervention (not specified in detail)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline self-confidence scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Number of vaginal hysterectomies performed before the educational intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-confidence scale
Number of subjects: 0
Study: 20413036

Group type: EXPERIMENTAL
Intervention: hANP infusion (0.02 microg/kg/min)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo (saline) infusion
Number of subjects: 133
Study: 17953462

Group type: EXPERIMENTAL
Intervention: OGT oral spray taken five times daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saliveze
Number of subjects: 41
Study: 15590244

Group type: EXPERIMENTAL
Intervention: Multisensory therapy (n = 36 sessions for 12 weeks)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Activity therapy (n = 36 sessions for 12 weeks)
Number of subjects: 89
Study: 12395981

Group type: EXPERIMENTAL
Intervention: FDC tablet containing rifampicin, isoniazid, pyrazinamide, and ethambutol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Separate formulations of rifampicin, isoniazid, and pyrazinamide
Number of subjects: 14
Study: 10395837

Group type: COMPARATOR
Intervention: Zanamivir 2x daily for 5 days
Number of subjects: 1256

Group type: COMPARATOR
Intervention: Zanamivir 4x daily for 5 days
Number of subjects: 1256

Group type: COMPARATOR
Intervention: Zanamivir
Number of subjects: 1256
Study: 7675961

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 91

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 91
Study: 2115407

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous recombinant tissue-type plasminogen activator (rt-PA) (0.75 mg/kg over 1 hour)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: High-dose intravenous rt-PA (0.75 mg/kg over 1 hour; total dose, 100 mg over 6 hours)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: All groups (low-dose rt-PA, high-dose rt-PA, placebo)
Number of subjects: 67
Study: 6111212

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg daily
Number of subjects: 9

Group type: COMPARATOR
Intervention: Atenolol (100 or 200 mg)
Number of subjects: 9
Study: 31488064

Group type: EXPERIMENTAL
Intervention: Usual care plus HCV/HIV-Reduction Education Program (HCV/HIV-REP) for 24 weeks
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care for 12 weeks
Number of subjects: 240
Study: 29273083

Group type: COMPARATOR
Intervention: Information and advice
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Physiotherapy and information and advice
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Chiropractic care and information and advice
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Chiropractic care, physiotherapy, and information and advice
Number of subjects: 600
Study: 26525962

Group type: EXPERIMENTAL
Intervention: Tobacco-heating cigarettes
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Snus
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ultra-low machine yield tobacco-burning cigarettes
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (usual brand cigarettes)
Number of subjects: 150
Study: 25146062

Group type: EXPERIMENTAL
Intervention: Seidlitzia rosmarinus plus prazosin 1mg/day
Number of subjects: 98

Group type: COMPARATOR
Intervention: Prazosin 1mg/day
Number of subjects: 98
Study: 20852079

Group type: EXPERIMENTAL
Intervention: Dietary florfenicol (0.02 g/kg; 16 wk)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sequential use of florfenicol (0.02 g/kg; 8 wk) and DVAQUA (0.5 g/kg; 8 wk)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dietary DVAQUA (0.5 g/kg; 16 wk)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 19552597

Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 21
Study: 17633908

Group type: EXPERIMENTAL
Intervention: Centralized telephone intervention program delivering continuity of care by a multidisciplinary team
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: Patients in advanced functional class
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: Patients with ischemic etiology
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: Patients in NYHA class I-II and without ischemic etiology
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: Patients admitted for decompensated heart failure
Number of subjects: 9000
Study: 16381264

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.04 microg/kg/min
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propofol infusion starting at 2 mg/kg/h reduced to 1 mg/kg/h
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (Remifentanil and Propofol)
Number of subjects: 50
Study: 12215235

Group type: EXPERIMENTAL
Intervention: Bupropion sustained release (SR) for 12 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Bupropion sustained release (SR)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 9468749

Group type: EXPERIMENTAL
Intervention: Restraint Scale (RS)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cognitive Restraint Scale of the Three Factor Eating Questionnaire (TFEQ‐CR)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Negative mood manipulation
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Neutral mood manipulation
Number of subjects: 104
Study: 8904056

Group type: EXPERIMENTAL
Intervention: Aspirin (80 mg daily)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 1974142

Group type: EXPERIMENTAL
Intervention: sufentanil 20 micrograms kg‐1 + somatostatin + trimetaphan
Number of subjects: 18

Group type: COMPARATOR
Intervention: sufentanil + sodium nitroprusside
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: sufentanil + somatostatin + trimetaphan
Number of subjects: 18
Study: 64972

Group type: EXPERIMENTAL
Intervention: programmed instruction (PI)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: audiovisual (AV)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: AV-PI combined
Number of subjects: 137

Group type: COMPARATOR
Intervention: no exposure to the mini-course (control group)
Number of subjects: 137
Study: 30920097

Group type: EXPERIMENTAL
Intervention: GC Gold Label 1 Luting & Lining (GIC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Relyx U200 (RUC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Relyx ARC (RAC)
Number of subjects: 30
Study: 29800096

Group type: EXPERIMENTAL
Intervention: Bougie (n=381)
Number of subjects: 757

Group type: COMPARATOR
Intervention: Endotracheal tube + stylet (n=376)
Number of subjects: 757
Study: 26655421

Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg daily orally) with bendamustine plus rituximab
Number of subjects: 578

Group type: COMPARATOR
Intervention: Placebo with bendamustine plus rituximab
Number of subjects: 578
Study: 24576466

Group type: EXPERIMENTAL
Intervention: Completed egoistic action
Number of subjects: 0

Group type: COMPARATOR
Intervention: Completed altruistic action
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intended (im)moral actions
Number of subjects: 0
Study: 22992073

Group type: EXPERIMENTAL
Intervention: BG-12 (dimethyl fumarate) 240 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BG-12 (dimethyl fumarate) 240 mg three times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BG-12 (dimethyl fumarate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19240689

Group type: EXPERIMENTAL
Intervention: NV1FGF plasmid DNA (0.5, 2, or 4 mg administered as eight IM injections)
Number of subjects: 6
Study: 17030096

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15699265

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glibenclamide (5 mg)
Number of subjects: 10
Study: 11874743

Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medication
Number of subjects: 2819

Group type: EXPERIMENTAL
Intervention: Eligibility visual field tests
Number of subjects: 2819

Group type: EXPERIMENTAL
Intervention: Repeat test after abnormal or unreliable test
Number of subjects: 2819

Group type: EXPERIMENTAL
Intervention: 33% fixation loss cutoff
Number of subjects: 2819
Study: 10022444

Group type: EXPERIMENTAL
Intervention: Human BNP infusion (3.0 pmol/kg min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NEP inhibitor (SCH 42495, 300 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined BNP and NEP inhibitor
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7778470

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure greater than 85 mmHg
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Low or normal diastolic blood pressure
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Low blood pressure
Number of subjects: 1070
Study: 2081639

Group type: EXPERIMENTAL
Intervention: Live attenuated lyophilized Schwartz strain of measles vaccine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Non-vaccinated group
Number of subjects: 132
Study: 7002178

Group type: EXPERIMENTAL
Intervention: Tofizopam 100 mg
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 31478933

Group type: EXPERIMENTAL
Intervention: Risk score based on 9 preoperative risk factors
Number of subjects: 8871

Group type: EXPERIMENTAL
Intervention: Preoperative delirium
Number of subjects: 8871

Group type: EXPERIMENTAL
Intervention: Preoperative dementia
Number of subjects: 8871

Group type: EXPERIMENTAL
Intervention: Age 70-79
Number of subjects: 8871

Group type: EXPERIMENTAL
Intervention: Age 80-89
Number of subjects: 8871

Group type: EXPERIMENTAL
Intervention: Age ≥90
Number of subjects: 8871

Group type: EXPERIMENTAL
Intervention: Medical comanagement
Number of subjects: 8871

Group type: EXPERIMENTAL
Intervention: ASA physical status III-V
Number of subjects: 8871

Group type: EXPERIMENTAL
Intervention: Functional dependence
Number of subjects: 8871

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 8871

Group type: EXPERIMENTAL
Intervention: Systemic inflammatory response syndrome/sepsis/septic shock
Number of subjects: 8871

Group type: EXPERIMENTAL
Intervention: Preoperative use of mobility aid
Number of subjects: 8871
Study: 31657508

Group type: EXPERIMENTAL
Intervention: Autism-Focused Public Speech Training using Simple Virtual Audiences (APSV)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Independent Study (IS)
Number of subjects: 15
Study: 29970053

Group type: EXPERIMENTAL
Intervention: Iron-folic acid supplements provided by trained BRAC village volunteers during early pregnancy
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 30000
Study: 27378790

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 μg/kg/min for 24 h without a loading dose)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23937690

Group type: EXPERIMENTAL
Intervention: Magnetic stimulation (1 Hz for 1 min) over both left and right angular gyrus (AG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Right AG-rTMS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study: 22781640

Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (routine therapy only)
Number of subjects: 172
Study: 20429955

Group type: EXPERIMENTAL
Intervention: VR training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Computer-assisted instruction (CAI)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: VR-ATM
Number of subjects: 24
Study: 18729579

Group type: EXPERIMENTAL
Intervention: Repair writing task
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control writing task
Number of subjects: 305
Study: 15906078

Group type: EXPERIMENTAL
Intervention: Cycle exercise (90% of the individual anaerobic threshold for 60-90 min)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Pure eccentric down jumps (9 x 28 isolated down jumps in 90 min, drop from a height of 55 cm)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control experiment
Number of subjects: 17
Study: 12728461

Group type: EXPERIMENTAL
Intervention: 5 ppm NO via inhalation followed by a recruitment maneuver (RM) with sustained inflation pressure of 30‐35 cmH2O for 30 seconds (Group 1)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Recruitment maneuver (RM) alone (Group 2)
Number of subjects: 23

Group type: COMPARATOR
Intervention: NO inhalation alone (Group 3)
Number of subjects: 23
Study: 10383502

Group type: COMPARATOR
Intervention: OAC regimen (omeprazole 20 mg b.d., amoxycillin 500 mg t.d.s., clarithromycin 200 mg b.d.)
Number of subjects: 221

Group type: COMPARATOR
Intervention: LAC regimen (lansoprazole 30 mg b.d., amoxycillin 500 mg t.d.s., clarithromycin 200 mg b.d.)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: RAC regimen (rabeprazole 20 mg b.d., amoxycillin 500 mg t.d.s., clarithromycin 200 mg b.d.)
Number of subjects: 221
Study: 8848769

Group type: EXPERIMENTAL
Intervention: Pasteur vaccine (5 micrograms at 0, 1, 2, 6, 18 months)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Recombinant vaccine (40 micrograms at 0, 1, 2, 6, 12 months)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No additional doses
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Monitoring and administration of additional doses
Number of subjects: 52
Study: 1906584

Group type: COMPARATOR
Intervention: Insulin alone (n = 22)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combined insulin-glibenclamide therapy (n = 25)
Number of subjects: 47
Study: 6341191

Group type: EXPERIMENTAL
Intervention: Urol medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spasmoanalgetic therapy
Number of subjects: 0
Study: 31829220

Group type: EXPERIMENTAL
Intervention: PRISMA program in addition to usual care
Number of subjects: 193

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: PRISMA program
Number of subjects: 193
Study: 28426542

Group type: EXPERIMENTAL
Intervention: Massage (20-minute aromatherapy foot massage)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Inhalation aromatherapy (3-minute inhalation before chemotherapy cycles)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (routine treatment only)
Number of subjects: 75
Study: 26707194

Group type: EXPERIMENTAL
Intervention: ADBLOCK system
Number of subjects: 0
Study: 25476075

Group type: EXPERIMENTAL
Intervention: Fibrobronchoscopic drainage in low CPEF group (at least once a day, frequency increased as needed)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Fibrobronchoscopic drainage in high CPEF group (when necessary)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Extubation success without re-intubation within 48 hours
Number of subjects: 102

Group type: COMPARATOR
Intervention: Comparison of ICU stay duration
Number of subjects: 102

Group type: COMPARATOR
Intervention: Comparison of re-intubation rates
Number of subjects: 102

Group type: COMPARATOR
Intervention: Comparison of APACHEII scores
Number of subjects: 102

Group type: COMPARATOR
Intervention: Comparison of mechanical ventilation time
Number of subjects: 102
Study: 22513491

Group type: EXPERIMENTAL
Intervention: School environment intervention with family involvement
Number of subjects: 454

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 454
Study: 21141322

Group type: EXPERIMENTAL
Intervention: Intra-operative 5-Fluorouracil (5-FU)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Post-operative sub-conjunctival 5-Fluorouracil (5-FU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no 5-FU)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study: 17413035

Group type: EXPERIMENTAL
Intervention: 6R‐BH4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6S‐BH4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NH4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetylcholine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glyceryl trinitrate
Number of subjects: 0
Study: 15848554

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS; 720 mg bid)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF; 1000 mg bid)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both EC-MPS and MMF
Number of subjects: 40
Study: 12165939

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9807606

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 61

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 61
Study: 7616802

Group type: EXPERIMENTAL
Intervention: Heparin (1250 IU twice a day subcutaneously for 30 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prednisone (10 mg per day for 30 days)
Number of subjects: 20
Study: 2691480

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate
Number of subjects: 359

Group type: COMPARATOR
Intervention: Metronidazole plus gentamicin
Number of subjects: 359
Study: 4499921

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study: 31773199

Group type: EXPERIMENTAL
Intervention: Bowel preparation
Number of subjects: 105

Group type: COMPARATOR
Intervention: No bowel preparation
Number of subjects: 105
Study: 31174395

Group type: EXPERIMENTAL
Intervention: Handgrip strength (HGS) measured using a hydraulic hand dynamometer
Number of subjects: 2045
Study: 28089764

Group type: EXPERIMENTAL
Intervention: Tailored online coaching with EHR tracking tools (CC)
Number of subjects: 194

Group type: COMPARATOR
Intervention: EHR tracking tools alone (TO)
Number of subjects: 194
Study: 25927183

Group type: EXPERIMENTAL
Intervention: Individualized perioperative group: intra‐ and postoperative individualized strategy
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Intraoperative individualized strategy + postoperative continuous positive airway pressure (CPAP)
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Intraoperative standard ventilation + postoperative CPAP
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Intra‐ and postoperative standard strategy (conventional strategy)
Number of subjects: 1012
Study: 23723099

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT) in the fasted state (FAST)
Number of subjects: 16

Group type: COMPARATOR
Intervention: High-intensity interval training (HIT) in the fed state (FED)
Number of subjects: 16